Trial Profile
A Double-blind, Escalating Dose, Randomized, Placebo-controlled Study to Assess the Pharmacokinetics, Safety and Tolerability of Single Subcutaneous Injections of GSK2402968 in Non-ambulant Subjects With Duchenne Muscular Dystrophy
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 04 Nov 2023
Price :
$35
*
At a glance
- Drugs Drisapersen (Primary)
- Indications Duchenne muscular dystrophy
- Focus Adverse reactions; Pharmacokinetics
- Acronyms DEMAND I
- Sponsors GlaxoSmithKline; GSK
- 23 Apr 2015 According to BioMarin media release, data presented at the American Academy of Neurology (AAN) Annual Meeting.
- 24 Mar 2014 New trial record